Lynette MS, Marina V. Epidemiology. In: Allen TC, editor. Diffuse Malignant Mesothelioma. Springer New York;2015:3-32.
Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1(4):491–6.
Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos.Ind Health. 2007;45:379-87.
Driscoll T, Nelson DI, Steenland K, et al. The global burden of disease due to occupational carcinogens. Am J Ind Med. 2005;48(6):419-31.
Spirtas R, Heineman EF, Bernstein L, et al. Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med. 1994;51(12):804–11.
Craighead JE. Epidemiology of mesothelioma and historical background. In: Tannapfel A, editor.Malignant mesothelioma. Heidelberg: Springer;2011:13-25.
World Health Organization. Chrysotile asbestos [Internet]. Geneva: WHO;2014.[cited 2018 Jan 5]. Available from:www. who.int/ipcs/assessment/public.../chrysotile_asbestos_summary. pdf
Maxim LD, Niebo R, Utell MJ. Are pleural plaques an appropriate endpoint for risk analyses? InhalToxicol. 2015;27(7):321-34.
Hillerdal G, Henderson D. (1997). Asbestos, asbestosis, pleural plaques and lung cancer. Scand J Work Environ Health. 23:93–103.
Subhannachart P, Dumavibhat N, Siriruttanapruk S. Asbestosrelated diseases in Thailand and review literature. J Med Assoc Thai. 2012;95(Suppl 8):S71-6
Chuaychoo B, Luangdansakun N, Chierakul N, et al. Pathological confirmed diagnosis of asbestosis: the first case report in Thailand. J. Med. Assoc. Thai. 2015;98(3):314-19.
